So said Shams Ruston from Labopharm at last week's Interphex conference in New York. We happen to agree. In fact, there are two ways to look at this. From the…
Yesterday, we responded on LinkedIn to the following note: THis is our first BIO conference in June and want to make it a great one. Any hints or helpful suggestions…
AOL sells patents to Microsoft. Why? The reasons for AOL selling these patents are pretty clear: Shares of AOL surged as much as 45% Monday, hitting their highest point in…
The past seven days have brought us two very interesting transactions. First, on March 14, Lyon-based Flamel announced their acquisition of St. Louis-based Eclat Pharmaceuticals. The press release contains a…
Earlier this week we learned that Pfizer will return to Biocon rights to biosimilar versions of various insulin derivatives: As of March 12, 2012, all rights licensed to Pfizer will…
The February, 2012 issue of Life Science Leader has a wide-ranging interview with G. Steven Burrill. It's an interesting, insightful read, and we can recommend the interview. Mr. Burrill makes…
UPDATE (21 February) - Here is a decent video interview of Rachel Sherman, head of the Office of Medical Policy for the FDA, on the Biosimilar guidelines: BioCentury This Week Today…
Last week, the NY Times published an interesting article on the cause of Alzheimer's Disease. The article describes experiments in a new mouse model which may confirm, once and for…
Lacerta Bio has returned to cold, windy New York following a solid week in sunny, warm San Francisco. We blogged about last year's JP Morgan Healthcare conference here . For…
Last month, Lacerta Bio celebrated its first full year in existence. In fact, our coming out event was JP Morgan 2011. What have we learned in a year? Probably too…